Hedge the rise in your health insurance premium with these 2 ASX stocks

Sick of price rises? Get on the other side of the transaction.

Health insurance premiums are set to rise by an average of 3.73% on 1 April. While this can be a bitter pill to swallow for consumers, it can be a good opportunity for investors.

To hedge the price hike, ASX investors could consider adding companies that stand to benefit to their portfolios.

Three health professionals at a hospital smile for the camera.

Image source: Getty Images

Changes go into effect on 1 April

After several rounds of negotiations between Health Minister Mark Butler and insurance companies, health insurance premiums will rise by an average of 3.73% in April. 

Each year, the health minister must approve the annual premium rises of private health insurance. This directly impacts more than half of Australia's population, with an estimated 13.6 million Australians having private health insurance, according to The Department of Health and Aged Care. 

This marks an acceleration from last year, when health premiums rose by an average of 3.03%. It also represents the largest increase in seven years. 

Instead of simply absorbing the rise in premiums, investors can benefit from the price hike by investing in the companies themselves. 

Some healthcare funds, such as the two listed below, have above-average price rises.

Medibank Private Ltd (ASX: MPL)

Medibank Private is Australia's largest private health insurance provider. Covering more than 4.2 million customers in 2024, Medibank directly benefits from higher health insurance premiums. Next month, Medibank will increase its premium by 3.99%. 

Medibank has proven a fruitful investment over the past five years, with its share price increasing more than 65%. Medibank also offers a dividend yield of 3.89%.

NIB Holdings Ltd (ASX: NHF)

Another health insurance company that is increasing its premiums above the average is NIB. It provides health and medical insurance to more than 1.5 million Australian and New Zealand residents. Next month, it will increase premiums by 5.79%, significantly above the average.

While not quite as attractive as Medibank Private, NIB has increased more than 30% over the past five years and offers a dividend yield of 4.02%.

Foolish takeaway

With rising inflation, price hikes have been a common theme over the past few years. In this case, those impacted by health insurance price rises can hedge their expenses by getting on the other side of the transaction and investing in the health insurance companies themselves. Funds with higher increases than the average may be especially compelling.

If the next five years are anything like the last five years, investing in Medibank Private and NIB could be a wise move.

Motley Fool contributor Laura Stewart has no positions in any of the stocks mentioned.The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »